Cessation of strontium ranelate supplyBMJ 2017; 357 doi: https://doi.org/10.1136/bmj.j2580 (Published 26 May 2017) Cite this as: BMJ 2017;357:j2580
- Mark J Bolland, associate professor of medicine,
- Andrew Grey, associate professor of medicine
- Department of Medicine, University of Auckland, Private Bag 92019, Auckland 1124, New Zealand
To our knowledge, there has been no response to our article1 from the European Medicines Agency (EMA), the manufacturer of strontium ranelate (Servier), or the academics involved in the phase III trials of strontium.
A news release on the Servier website dated 14 March 2017, however, says that Servier sent a letter on 10 February 2017 to …